东宝生物：10月28日召开董事会会议

Company Overview - Dongbao Biological (SZ 300239) announced the convening of its 14th meeting of the 9th Board of Directors on October 28, 2025, to review the proposal for the "2025 Third Quarter Report" [1] - The company's revenue composition for the year 2024 is entirely from biological and biochemical products, accounting for 100.0% [1] - As of the report, Dongbao Biological has a market capitalization of 3.4 billion yuan [1] Industry Context - The A-share market has surpassed 4000 points, marking a significant resurgence after a decade of stagnation, with technology leading the market's transformation [1] - This shift indicates the emergence of a "slow bull" market pattern, suggesting a new phase in market dynamics [1]